Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy

Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study

(2015) J. Donadieu et al.   BLOOD

How I treat Langerhans cell histiocytosis

(2015) C. E. Allen et al.   BLOOD

Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning

(2015) Paul A. Veys et al.   BRITISH JOURNAL OF HAEMATOLOGY

When should we consider transplantation in adult patients with sclerosing cholangitis due to multisystem Langerhans’ cell histiocytosis?

(2015) Julien Scanzi et al.   DIGESTIVE AND LIVER DISEASE

MAP2K1andMAP3K1mutations in langerhans cell histiocytosis

(2015) David S. Nelson et al.   GENES CHROMOSOMES & CANCER

Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease

(2015) Julien Haroche et al.   JOURNAL OF CLINICAL ONCOLOGY

Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis

(2015) Julien Haroche et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective Study

(2015) Deepak Chellapandian et al.   PEDIATRIC BLOOD & CANCER

Early Diagnosis and Monitoring of Neurodegenerative Langerhans Cell Histiocytosis

(2015) Elena Sieni et al.   PLoS One

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis

(2015) Sébastien Héritier et al.   JAMA Oncology

A(nother) RAF mutation in LCH

(2014) K. Shannon et al.   BLOOD

Somatic activating ARAF mutations in Langerhans cell histiocytosis

(2014) D. S. Nelson et al.   BLOOD

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis

(2014) N. A. Brown et al.   BLOOD

Blood spotlight on Langerhans cell histiocytosis

(2014) C. Delprat et al.   BLOOD

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

(2014) R. Chakraborty et al.   BLOOD

Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood

(2014) Maurizio Aricò et al.   BRITISH JOURNAL OF HAEMATOLOGY

Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone?

(2014) Stephen J. Simko et al.   BRITISH JOURNAL OF HAEMATOLOGY

Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease

(2014) Shinsaku Imashuku et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

BRAF-V600Eexpression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

(2014) Marie-Luise Berres et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Symptomatic Bone Langerhans Cell Histiocytosis Treated at Diagnosis or After Reactivation With Indomethacin Alone

(2014) Jorge Braier et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

(2013) H. Gadner et al.   BLOOD

Clinical Features and Treatment Outcomes of Langerhans Cell Histiocytosis

(2013) Bo Eun Kim et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease

(2013) Stephen J. Simko et al.   PEDIATRIC BLOOD & CANCER

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

(2012) J. Haroche et al.   BLOOD

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

(2012) J. Haroche et al.   BLOOD

Langerhans cell histiocytosis: pragmatic empirism on the road to rational cure

(2012) Milen Minkov   EXPERT OPINION ON PHARMACOTHERAPY

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pulmonary langerhans cell histiocytosis

(2012) Harpreet S Suri et al.   Orphanet Journal of Rare Diseases

Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis

(2012) Allistair Abraham et al.   PEDIATRIC BLOOD & CANCER

Langerhans Cell Histiocytosis of the Orbit: Five Clinicopathologic Cases and Review of the Literature

(2012) Martina C. Herwig et al.   SURVEY OF OPHTHALMOLOGY

Recurrent BRAF mutations in Langerhans cell histiocytosis

(2010) G. Badalian-Very et al.   BLOOD

The role of BMT in childhood histiocytoses

(2008) D Caselli et al.   BONE MARROW TRANSPLANTATION

Reactivations in Multisystem Langerhans Cell Histiocytosis: Data of the International LCH Registry

(2008) Milen Minkov et al.   JOURNAL OF PEDIATRICS

Clofarabine in refractory Langerhans cell histiocytosis

(2008) Carlos Rodriguez-Galindo et al.   PEDIATRIC BLOOD & CANCER